4SC’s vidofludimus Phase IIa research in IBD meets primary endpoint 4SC AG , a drug discovery and development company centered on autoimmune and cancer indications, today announced positive preliminary results of a Stage IIa study in inflammatory bowel disease using its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 release. The exploratory, open-label, single-arm Stage IIa ENTRANCE study met its major endpoint of significantly increasing the response rate in corticosteroid-dependent IBD patients to 88 online pharmacy .5 percent versus the average placebo response across published benchmark medical trials of approximately 20 percent.
We wouldn't be able to put on the event without the help of our excellent bands and volunteers; they really smoothly make the event roll. Lastly definitely, we want to thank our presenting and platinum sponsors for making this event possible. You want to send out out a special thanks to our Presenting sponsors: Evan Williams, Svedka, Don Q Rum, Lunazul Tequila, Fireball Whiskey, and Q-104.5. We’d also prefer to thank our Platinum sponsors: Sea Fox Boats, Matchstick Public, and JTE Advertising Group. Â.. 4th annual ‘Rockers4knockers’ fundraising event to be held in Mt. Pleasant on October 5, 2014 For the fourth consecutive year, 'Rockers4Knockers' will be rocking Shem Creek in Mt.